Tuberculosis in Greenland. Bolette Søborg MD, PhD Dept. of Epidemiology Research Statens Serum Institut

Similar documents
INFECTIOUS DISEASES IN THE ARCTIC AN OVERVIEW

AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK

Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review

In the 1950s, the Inuit population in Greenland, Ongoing tuberculosis transmission to children in Greenland

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive Houston, Texas October 15-17, 2013

Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials

Thorax Online First, published on December 8, 2009 as /thx

Approaches to LTBI Diagnosis

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

ESCMID Online Lecture Library. by author

TB Prevention Who and How to Screen

Latent Tuberculosis and Tuberculosis

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

New NICE guideline updates recommendations for diagnosing latent tuberculosis

Diagnosis Latent Tuberculosis. Disclosures. Case

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

TB Intensive Tyler, Texas December 2-4, 2008

TB, BCG and other things. Chris Conlon Infectious Diseases Oxford

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

A 100 year update on diagnosis of latent tuberculosis infection From TST to IGRA

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Identifying TB co-infection : new approaches?

QuantiFERON-TB Gold Plus

Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation

Update on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

Update on IGRA Predictive Value

El futuro del diagnostico de la ITL. en tiempos de crisis. Professor Ajit Lalvani FMedSci Chair of Infectious Diseases

Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis

Jeffrey R. Starke, M.D. has the following disclosures to make:

Screening and management of latent TB Infection Gerry Davies

Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*

Interpretation of TST & IGRA results. Objectives

QFT. 457 QuantiFERON -TB 2nd Generation QFT m 2 キーワーズ QFT QFT QFT QFT BCG. Kekkaku Vol. 85, No. 6: 547_552, 2010

Experience with maternal pertussis and PCV13 immunisation in England

Peggy Leslie-Smith, RN

Comparative evaluation of diagnostic performance of Xpert between paired IS and GW in children <3.5 years in Cape Town, SA

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Author's response to reviews

Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold?

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

Predictive values of IGRAs and TST for progression to active disease in TB. 3 rd Global IGRA Symposium January 2012.

Technical Bulletin No. 172

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Dimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis

PREVALENCE OF HIV INFECTION AND RISK FACTORS OF TUBERCULIN INFECTION AMONG HOUSEHOLD CONTACTS IN AN HIV EPIDEMIC AREA: CHIANG RAI PROVINCE, THAILAND

Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service

The Most Widely Misunderstood Test of All

Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

The Origin of Swine Flu

Time interval to conversion of interferon-c release assay after exposure to tuberculosis

The evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection

Tuberculosis in Greenland current situation and future challenges

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study

Madhukar Pai, MD, PhD Jessica Minion, MD

Step-by-Step Immunization Compliance Guide STUDENT HEALTH SERVICES

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

A Review on Prevalence of TB and HIV Co-infection

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Tuberculosis Elimination

TB-Free California: How close are we? How can we get closer?

Pediatric Tuberculosis in Los Angeles County: An Update

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Didactic Series. Latent TB Infection in HIV Infection

Latent Tuberculosis in Adults: From Testing TO Treatment

DANISH GUIDELINES FOR PREVENTION AND TREATMENT OF TB IN CHILDREN

TB Intensive San Antonio, Texas

Contact Investigation Overview

Northwestern Polytechnic University

Diagnosis & Management of Latent TB Infection

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment

Estimating the global burden of tuberculosis. WHO estimates of TB incidence, prevalence and mortality, by country,

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors

Ongoing Research on LTBI and Research priorities in India

IS VITAMIN D IMPORTANT IN THE MANAGEMENT OF TUBERCULOSIS?

Tuberculosis Elimination Jennifer Flood, MD, MPH Pennan Barry, MD, MPH NAR-NTCA February 25, 2016

Why need to havetb Clearance. To Control and Prevent Tuberculosis

Tuberculosis Intensive

Monitoring latent tuberculosis infection diagnosis and management in the Netherlands

TB Update: March 2012

The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ

Transcription:

Tuberculosis in Greenland Bolette Søborg MD, PhD Dept. of Epidemiology Research Statens Serum Institut

Historical perspective

Prevalence of M. tuberculosis infection CROSS SECTIONAL TUBERCULIN SKIN TEST SURVEY CHILDREN, SOUTHERN GREENLAND, 1933 866 Participants, ½-20 years of age (50% of relevant population) ½-6 years: 43% TST positive 7-13 years: 86% TST positive 14-19 years: 100% TST positive Bertelsen, A. Grønlandsk medicinsk Statistik og Nosografi I IV, Medd. om Grønland CXVII, 1943. bot@ssi.dk

Tuberculosis incidence 1956-2012 TB cases reported to the Chief medical officer of Greenland. 1956-2012 Courtesy of the Chief Medical Officer in Greenland, annual report 2013

TB cases reported to the Chief medical officer of Greenland1984-2012 Courtesy of the Chief Medical Officer in Greenland, annual report 2013 bot@ssi.dk

Tuberculosis notification, WHO 2012 Bolette Søborg, bot@ssi.dk Global TB Control Report, WHO 2012

Number of TB cases in periods with high and low incidence

TB cases per age group Age groups in years TB incidence* 1975-1989 TB incidence* 1990-2010 Trend for the period 1990-2010 (p-value) 0-4 6 59 0.3 5-14 8 67 0.7 15-24 27 173 <0.0001 25-34 29 135 0.0003 35-44 33 113 0.02 45-54 66 137 0.35 55-64 88 159 0.08 65+ 49 163 0.04

Prevalence of M. tuberculosis infection by age Bolette Søborg, bot@ssi.dk

Effect of national interventions Bolette Søborg, bot@ssi.dk

Ten years of tuberculosis intervention in Greenland - Has it prevented cases of childhood tuberculosis? Period TB cases IRR 95% CI p 1990-1994 23 0.47 (0.28-0.75) 0.002 1995-1999 64 1 (Ref.) - - 2000-2006 93 1.05 (0.76-1.45) 0.78 2007-2010 29 0.62 (0.39-0.95) 0.03 Total 209 0.0004 E. Birch et al. J. Circumpolar Health, 2014

Bolette Søborg, bot@ssi.dk

Outbreak 2010-2012

TB notification rate East Greenland 1977-2014 A: n/ 100,000 inhabitants 2000 1500 1000 500 Mtb infected school children Settlement X: 0% Rest of East Greenland: 8% Increasing in Settlement X 0 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 B: K.B. Mortensen et al Eur Respir J. 2015 15 Settlement X Confirmed

TB incidence rates (IR) and incidence rate ratios (IRR) East Greenland 2008-2012 Settlement X Rest of East Greenland Cases IR /100,000 Cases Personyears Personyears IR /100,000 IRR Total 28 1,668 1,730 99 15,360 704 2.48 0-12 yrs - 380-3 3,631 90-13-19 yrs 18 251 7,389 39 2,056 2,210 4.08 20+ yrs 10 1,036 1,000 57 9,671 633 1.49 K.B. Mortensen et al Eur Respir J. 2015

Mtb infection prevalence Jan 1, 2013, East Greenland (IGRAs, n= 4,060) 61% Settlement X 79% teenagers 56% adults 48% children 38% Rest of East Greenland 48% adults 42% teenagers 14% children K.B. Mortensen et al Eur Respir J. 2015

Effect of BCG vaccination

Host Immunity to Tuberculosis in Greenland Sascha Wilk Michelsen, MD, PhD student Supervisors: Melbye M, Soborg B, Koch A, Agger EM, Hoff ST

AIM How effective is the BCG vaccine in preventing tuberculosis infection and disease? Is immunity to latency antigens associated with prevention of progression to TB? Is immunity to Mtb antigens specific for infection stages and is immunity sustained over time? swm@ssi.dk

BCG REDUCED THE ODDS OF TB INFECTION N = 953, BORN IN GREENLAND, AGE 5-30 YEARS, PARTICIPATION RATE 80% Predicted TB infection prevalence by age (%) NOT vaccinated TB infection overall 29% Among vaccinated 23% Among non-vaccinated 56% % Odds ratio for TB infection in BCG vaccinated Adjusted OR 0.52 (95% CI 0.32-0.85) p = 0.01 BCG reduced the risk of TB infection by 20% Age in years Michelsen et al Thorax 2014 swm@ssi.dk

BCG REDUCED THE RISK OF TB DISEASE COHORT N = 1,597, AGE 5-30 YEARS, FOLLOW UP: 21,148 PERSON YEARS Cumulative risk of TB disease by age (%) % TB disease overall 6% Among vaccinated 4% Among non-vaccinated 11% TB incidence 440/100,000 Harazd ratio for TB disease in BCG vaccinated Adjusted HR 0.50 (95% CI 0.26-0.95) p = 0.03 BCG reduced the risk of TB disease by 50% Age in years Michelsen et al Thorax 2014 swm@ssi.dk

IMMUNITY TO LATENCY ANTIGENS DID NOT REDUCE RISK OF SUBSEQUENT TB COHORT N=911, AGE 5-31 YEARS, FOLLOW UP 1,985 PERSON YEARS Unpublished data Michelsen SW, Soborg B, Agger EM, Diaz LJ, Hoff ST, Koch A, Sorensen HC F, Andersen P, Wohlfahrt J, Melbye M swm@ssi.dk 26

CHANGES IN IMMUNITY TO MTB ANTIGENS AND RISK OF TB TB FOLLOW UP 2 YEARS Neither increasing nor decreasing immunity to non-igra antigens was found to be associated with risk of subsequent TB. A substantial increase in immunity to IGRA antigen CFP10 was associated with 10-fold increased risk of subsequent TB HR 10.06 (95% CI 1.05-96.25) Unpublished data Michelsen SW, Soborg B, Diaz LJ, Hoff ST, Agger EM, Koch A, Rosenkrands I, Wohlfahrt J, Melbye M swm@ssi.dk 27

Thank you for listening bot@ssi.dk